Human Rabies Immunoglobulin Market Size, Share & Industry Analysis, By Type (ERIG and HRIG), By Application (Category II Exposure and Category III Exposure) Covid-19 Impact, Latest Trends, Segmentation, Driving Factors, Restraining Factors, Key Industry Players, Regional Insights, and Forecast To 2031

Human Rabies Immunoglobulin Market Report Overview

• 

•  Request a Free Sample to learn more about this report

The global human rabies immunoglobulin market size was USD 396 million in 2021 and is projected to touch USD 726.21 million by 2031, at a CAGR of 6.2% during the forecast period. 

Antibodies against the rabies virus make up the drug rabies immunoglobulin (RIG). After exposure, it is used to prevent rabies. Figure Human Rabies Immunoglobulin (IM) is a rabies immunoglobulin antibody produced through the expensive low-temperature ethanol separation of healthy human plasma protein or through other approved separation and purification techniques, as well as the removal and inactivation of the virus. mostly used for the passive immunization of patients with rabies or other mad animal bites or scrapes.

COVID-19 Impact: Lockdown Restrictions to Impede Market Advancements 

The sudden spike in CAGR is attributable to human rabies immunoglobulin market growth and demand returning to pre-pandemic levels once the pandemic is over. The global COVID-19 pandemic has been unprecedented and staggering, with the human rabies immunoglobulin market experiencing lower-than anticipated demand across all regions compared to pre-pandemic levels.

The COVID-19 pandemic had induced harsh and unrelenting implications upon uncountable industries and its market, as COVID-19 virus determinedly grew on a global scale. However, the liposuction devices market accounted for a major decrease in demand and supply levels for the liposuction surgeries because numerous and constant researches had been occurring in each pharmaceutical company and sector to formulate a vaccination and treatment for the COVID-19 virus.

LATEST TRENDS

"Increasing Demand from Pharmaceutical Sector to Stimulate Higher Demand"

The country offers two different cell culture rabies vaccines made by various pharmaceutical companies; the majority of the vaccines are domestically produced, and the market for rabies vaccines is estimated to be worth INR 125 crores, with the northern region recording the highest sales, followed by the southern region. In the same way, there are two different forms of immunoglobulins: imported human immunoglobulins (HIGs) and locally produced equine rabies immunoglobulins (RIGs). RIGs have a market worth of roughly INR 83 crores. Since November 2017, a brand-new monoclonal antibody against rabies has been sold in the nation.

RESTRAINING FACTORS

"Side Effects to Restrain Market Growth"

Following the rabies vaccine, side effects may include headache, nausea, abdominal pain, muscle aches, or disorientation in addition to soreness, redness, swelling, or itching at the injection site. Sometimes, after booster doses, people have hives, joint pain, or fever.

Human Rabies Immunoglobulin Market Segmentation

• 

•  Request a Free Sample to learn more about this report

• By Type

Based on type; ERIG and HRIG.

• By Application

Based on application; Category II Exposure and Category III Exposure.

DRIVING FACTORS

"Rising Occurrences of Disease to Prosper Market Growth"

This market is expanding as a result of rising post-exposure prophylaxis demand, rising rabies incidence, and an increase in government and non-governmental organization rabies preventive programs.

A sterile preparation known as Human Rabies Immunoglobulin (IM) is created from pooled human plasma and is highly anti-rabies. It is used to immediately give rabies virus-exposed individuals passive immunity.

"Presence of Prominent Players in the Developing Regions to Boost Market Growth"

During the anticipated time frame, the market for human rabies immunoglobulins is anticipated to expand. The rising prevalence of rabies and the rise in demand for post-exposure prophylaxis are both factors contributing to the expansion of this market. This market's expansion is also being aided by the huge number of manufacturers and distributors that are located in developed nations.

Human Rabies Immunoglobulin Market Regional Insights

• 

•  Request a Free Sample to learn more about this report

"R&D Activities to Foster Growth in North America"

Due to the high concentration of major product manufacturers in North America, rising R&D spending, and increased research and development activities, the region holds the biggest human rabies immunoglobulin market share.

Asia Pacific region is anticipated to experience the quickest human rabies immunoglobulin market growth during the forecast period. High target population density, a high level of unmet medical demands, and the region's expanding economic growth are all variables that support industrial expansion.

KEY INDUSTRY PLAYERS

"Key Players Strategize to Increase Awareness of the Product"

The key market players aim to augment the amount of awareness of liposuction in the market due to the lack of knowledge amongst consumers. Furthermore, as awareness would spread and several users from diverse markets would understand the benefits, applications and outcomes of the liposuction devices and eventually grow demand. Additionally, the key players also advertise the products to increase sales and benefit their market share and position.

LIST OF TOP HUMAN RABIES IMMUNOGLOBULIN COMPANIES

• CSL Behring (U.S.)
• Grifols (Spain)
• Sanofi (France)
• Sichuan Yuanda Shuyang (China)
• CNBG (China)
• Kamada (Israel)
• CBPO
• VINS (India)
• Shuanglin Bio (China)
• Weiguang Bio (China)
• Shanghai RAAS (China)
• Bharat Serum (India)

REPORT COVERAGE

This report highlights types in the human rabies immunoglobulin market and the products latest trends along with its driving and restraining factors. Additionally, this report is inclusive of the key industry players and their current strategies and factors displaying the reasoning of why the leading region claims the term.